BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the...
Items per page:
1 - 1 of 1